AC Immune SA (ACIU) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AC Immune SA, a neuroscience-focused biopharmaceutical company, has announced the appointment of Dr. Anke Post as the new Chief Medical Officer (CMO), effective September 19, 2024. Dr. Post brings a wealth of experience from her previous roles in neuroscience and drug development at companies such as Roche, Eli Lilly, and Novartis. The outgoing CMO, Dr. Nuno Mendonça, is set to depart the company to explore new professional avenues.
For further insights into ACIU stock, check out TipRanks’ Stock Analysis page.